You are here

Electrophysiology & Arrhythmia

 

The first-ever proteome of the healthy human heart is complete, a team at the Technical University of Munich has reported—thanks to the successful logging of nearly 11,000 proteins and billions of cells.

From pocket-sized electrocardiograms to watches that measure blood glucose levels, the field of medical technology is rapidly evolving. But these innovations, though oftentimes successful, aren’t necessarily living up to what scientists want them to be, according to presenters at the American Heart Association’s Scientific Sessions 2017.

Men are more likely to receive bystander cardiopulmonary resuscitation (CPR) in public locations than women and are more likely to survive cardiac arrest in those situations, according to research presented Nov. 11 at the American Heart Association’s (AHA) scientific sessions in Anaheim, California.

A new left atrial appendage (LAA) closure device can be implanted with a high success rate and slashes the one-year risk of stroke in nonvalvular atrial fibrillation (NVAF) patients, according to the researchers of the device’s pilot trial.

More cardiac arrest victims will survive if emergency medical dispatchers give cardiopulmonary resuscitation (CPR) instructions over the phone and if infants and children receive rescue breaths in addition to chest compressions, according to updated CPR guidelines released Nov. 7 by the American Heart Association (AHA).

 

Recent Headlines

Improper dosing of NOACs may increase risk of mortality, cardiac hospitalization

Nearly 13 percent of patients with atrial fibrillation did not receive the correct dose of non-vitamin K antagonist oral anticoagulants (NOACs), according to a registry analysis.

Patients receiving dabigatran have high adherence rates, low risk of stroke, bleeding

A registry analysis found that patients with newly diagnosed non-valvular atrial fibrillation who received dabigatran (Pradaxa) had a 76.6 percent probability of remaining on treatment at one year and a 69.2 percent probability of remaining on treatment at two years.

Biotronik enrolls first patients in study evaluating BioMonitor 2 in office setting

Biotronik announced Dec. 5 that the first patients had enrolled in the BioInsight trial, which is evaluating the use of the BioMonitor 2 in an office setting.

Alcohol remains major risk factor for atrial fibrillation

Studies have shown that small amounts of alcohol could reduce the incidence of coronary disease. However, a recent review found that the benefits of alcohol do not apply to atrial fibrillation. In fact, the researchers noted that alcohol was a risk factor for atrial fibrillation, also known as an irregular heartbeat.

Medtronic agrees to operate cath, EP labs at Cleveland medical center

Medtronic has signed a deal to operate the catheterization and electrophysiology laboratories at the University Hospitals Cleveland Medical Center in Cleveland.

Be grateful this thanksgiving, your heart will appreciate it

Being extra thankful this Thanksgiving might give your heart health a boost, research suggests.

MMD patients have risk of conduction abnormalities, left ventricular dysfunction

More than 20 percent of patients with type I and type II myotonic muscular dystrophy (MMD) had critically prognostic conduction abnormalities, according to a small study at Johns Hopkins Hospital in Baltimore. In addition, more than 10 percent of the patients had left ventricular dysfunction.

Marijuana use could lead to stress cardiomyopathy

Though marijuana is now prescribed by medical professionals to help some patients cope with their health conditions, a new study shows that the drug could still do harm if used too frequently.

Pacemakers implanted following TAVR may increase mortality risk

Patients who were implanted with a pacemaker after undergoing transcatheter aortic valve replacement (TAVR) had a 31 percent higher one-year mortality rate compared with patients who did not receive a pacemaker following TAVR, according to a retrospective cohort study.

Taking dabigatran may reduce hospitalizations for non-valvular atrial fibrillation patients

A retrospective cohort analysis found that patients with non-valvular atrial fibrillation who were newly treated with dabigatran (Pradaxa) had significantly lower all-cause hospitalizations, emergency room visits and physician office visits compared with a group that received warfarin.

Pages